CME
CME Group Inc.
CME's fundamentals are mixed: revenue grew 9%, while its operating margin held steady at 66%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
IREN
IREN Limited
There isn't enough reported data to score IREN yet.
CME Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| N/A | |
| N/A |
CME's profitability is currently strong, and its revenue is stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like CME.
IREN Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| N/A | |
| N/A |
IREN's revenue and profitability are currently under pressure. Free cash flow and net leverage aren't meaningful measures for financial services companies like IREN.
CME PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 24x | $289 | -8.3% |
| Forward | 24x | $316 | — |
| Fair | 26x | $314 | -0.4% |
| Current | 26x | $316 | — |
| Expensive | 33x | $405 | +28% |
Historical ranges are pointers, not guarantees.
CME's PE is 26x, but its earnings don't support one, so it isn't a reliable read right now.
IREN PE Valuation
IREN has no meaningful PE right now: it lost money over the past year.
CME Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
CME has the edge over IREN on the outlook, with more favorable earnings expectations.
IREN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect IREN's losses to grow, with revenue growing. However, they disagree widely on these estimates.
CME Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $12.95 | +6.2% |
| Q3 2026 | $12.19 | +18% |
| Q2 2026 | $11.79 | +14% |
| Q1 2026 | $11.72 | +18% |
| Q4 2025 | $11.16 | +15% |
| Q3 2025 | $10.32 | +8.6% |
| Q2 2025 | $10.33 | +14% |
| Q1 2025 | $9.94 | +13% |
| Q4 2024 | $9.67 | +9.1% |
CME has the edge over IREN on earnings quality, reporting a profit while its opponent remains loss making.
IREN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.96 | -347% |
| Q2 2026 | -$2.22 | -988% |
| Q1 2026 | $0.51 | +$1.10 |
| Q4 2025 | $1.18 | +$1.62 |
| Q3 2025 | $1.60 | +$1.99 |
| Q2 2025 | $0.25 | +$0.45 |
| Q1 2025 | -$0.59 | -$0.43 |
| Q4 2024 | -$0.44 | -$0.15 |
IREN has swung to a loss: it lost $3.96 per share over the past year, after a profit the year before.
CME Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.7B | +13% |
| Q2 2026 | $1.7B | +0.8% |
| Q1 2026 | $1.9B | +14% |
| Q4 2025 | $1.6B | +8.1% |
| Q3 2025 | $1.5B | -3% |
| Q2 2025 | $1.7B | +10% |
| Q1 2025 | $1.6B | +10% |
| Q4 2024 | $1.5B | +6% |
CME's revenue has grown year over year for four quarters in a row: $1.7B last quarter, up 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +2.5 points |
| Q2 2026 | 65% | -1.8 points |
| Q1 2026 | 70% | +2.2 points |
| Q4 2025 | 62% | -0.3 points |
| Q3 2025 | 63% | -1.4 points |
| Q2 2025 | 67% | +1.4 points |
| Q1 2025 | 67% | +3 points |
| Q4 2024 | 62% | +2.1 points |
CME has the edge over IREN on profitability, with a higher operating margin.
IREN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $228M | -5.1% |
| Q2 2026 | $137.2M | -27% |
| Q1 2026 | $144.8M | 0% |
| Q4 2025 | $184.7M | +59% |
| Q3 2025 | $240.3M | +355% |
| Q2 2025 | $187.3M | +230% |
| Q1 2025 | $144.8M | +168% |
| Q4 2024 | $116.1M | +176% |
IREN's revenue has held roughly level: $228M last quarter, down 5.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -82% | -50 points |
| Q2 2026 | -452% | -461 points |
| Q1 2026 | -161% | -180 points |
| Q4 2025 | -63% | -79 points |
| Q3 2025 | -32% | +57 points |
| Q2 2025 | 9% | +49 points |
| Q1 2025 | 19% | +8 points |
| Q4 2024 | 15% | +21 points |
IREN's operating margin was −82% last quarter, down 50 points from the same quarter a year ago.
CME Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.1B | +13% |
| Q2 2026 | $923.5M | -11% |
| Q1 2026 | $1.2B | +12% |
| Q4 2025 | $1.1B | +11% |
| Q3 2025 | $949.7M | -2.4% |
| Q2 2025 | $1B | +37% |
| Q1 2025 | $1.1B | +26% |
| Q4 2024 | $991.7M | -3.1% |
CME has the edge over IREN on cash generation, producing positive trailing cash flow while its opponent burns cash.
IREN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.6B | -$1.6B |
| Q2 2026 | $482.2M | +2895% |
| Q1 2026 | -$873.8M | -$523.1M |
| Q4 2025 | -$468M | -$334M |
| Q3 2025 | -$38M | +$349.4M |
| Q2 2025 | $16.1M | +$179M |
| Q1 2025 | -$350.7M | -$128.7M |
| Q4 2024 | -$134M | -$105.2M |
IREN's free cash flow was −$2.5B over the past year, against −$507M the year before. Free cash flow isn't a meaningful measure for financial services companies like IREN.
CME Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.7% | -2.6M shares |
| 1 year | -0.5% | -1.8M shares |
| 3 years | -0.3% | -978K shares |
| 5 years | -0.1% | -347K shares |
| Available history | +0.1% | +402K shares |
CME has the edge over IREN on shareholder dilution, with a more favorable share count trend.
IREN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +26% | +82.4M shares |
| 1 year | +10% | +36.9M shares |
| 3 years | +511% | +333M shares |
| 5 years | +624% | +344M shares |
| Available history | +2346% | +382M shares |
IREN has 399M diluted shares, up 10% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
CME Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2020 | -0.4x | Net Cash |
| Q2 2020 | -0.4x | Net Cash |
| Q1 2020 | -0.3x | Net Cash |
| Q4 2019 | -0.6x | Net Cash |
CME has more cash than debt. Net leverage isn't a meaningful measure for financial services companies like CME.
IREN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | 157.6x | High |
| Q4 2025 | 22.2x | High |
| Q3 2025 | 4.1x | High |
| Q2 2025 | 2.0x | Moderate |
| Q1 2025 | 3.3x | Elevated |
| Q4 2024 | -4.6x | Net Cash |
| Q3 2024 | -16.7x | Net Cash |
| Q2 2024 | -15.9x | Net Cash |
IREN's net debt is more than 20 years of its operating earnings (EBITDA), up from 3.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like IREN.
CME Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 65.2 | Neutral |
| Stochastic | 89.3 | Overbought |
CME's weekly RSI is 65 (neutral) and its Stochastic is 89 (overbought).
IREN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.3 | Neutral |
| Stochastic | 8.2 | Oversold |
IREN's weekly RSI is 33 (neutral) and its Stochastic is 8 (oversold).
CME PE vs Financial Services Sector
| Metric | CME | Sector median | Relative |
|---|---|---|---|
| PE | 26x | 13x | 99% above |
| PE % | 51 | 63 | 12 pts below |
CME is trading at 26x earnings, a 99% premium to the Financial Services sector's median of 13x, though its earnings don't support one.
IREN PE vs Financial Services Sector
| Metric | IREN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 13x | — |
IREN has no meaningful PE right now: it lost money over the past year.
CME Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $291.5 | 8.2% above |
| 20 week MA | $275.2 | 15% above |
| 50 week MA | $280.9 | 12% above |
| 100 week MA | $272.5 | 16% above |
| 200 week MA | $238.3 | 32% above |
CME has the edge over IREN on trend strength, trading above more of its moving averages.
IREN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.8 | 35% below |
| 20 week MA | $36.2 | 46% below |
| 50 week MA | $42.8 | 54% below |
| 100 week MA | $32.0 | 39% below |
| 200 week MA | $19.1 | 2.1% above |
IREN has fallen below most of its moving averages, though it's still 2.1% above its 200-week average.
CME Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $202.8 | $178.5 | -12% |
| 2021 | $178.5 | $229.0 | +28% |
| 2022 | $229.0 | $173.3 | -24% |
| 2023 | $173.3 | $210.6 | +22% |
| 2024 | $210.6 | $233.5 | +11% |
| 2025 | $233.5 | $276.7 | +19% |
| 2026 YTD | $276.7 | $315.5 | +14% |
CME has the edge over IREN on returns for 2026, with the stronger performance.
IREN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $24.8 | $17.2 | -31% |
| 2022 | $17.2 | $1.19 | -93% |
| 2023 | $1.19 | $7.15 | +501% |
| 2024 | $7.15 | $10.7 | +50% |
| 2025 | $10.7 | $40.3 | +276% |
| 2026 YTD | $40.3 | $19.5 | -52% |
IREN's yearly returns have swung widely, from +501% in 2023 to −93% in 2022. It's down 52% so far in 2026.